Anti‑inflammatory effect of Migri‑Heal® in an in vitro inflammatory model of primary mixed glial cells.
Migri‑Heal®, is a novel herbal remedy that was introduced for the treatment of migraine headaches. Previous studies revealed that this drug may reduce nitric oxide (NO) in an in vitro inflammatory model. The aim of the present study was to investigate the anti‑inflammatory effect of Migri‑Heal® on primary mix glial cells stimulated with LPS. In the current study, neonatal rat primary mix glial cells were isolated from the mixed glial cultures via shaking, and cultured in Dulbecco's' modified Eagle's medium supplemented with 10% fetal bovine serum. Following pretreatment with Migri‑Heal® (25, 75, 100, 150, 200 and 300 µg/ml) and cells were treated with LPS (10 µg/ml) for 1 h, and incubated for 48 h. The present study determined that 150 µg/ml Migri‑Heal® signiﬁcantly reduced the production of NO in rat mix glial cells stimulated with 10 µg/ml LPS. Migri‑Heal® also suppressed mRNA expression level of LPS‑induced inducible nitric oxide synthase and tumor necrosis factor α, which was accompanied by inhibition of the transcription factor nuclear factor‑κB. Additionally, MTT assay determined that Migri‑Heal® was not cytotoxic, suggesting that the anti‑inflammatory effects of Migri‑Heal® observed were not due to cell death. In conclusion, the findings of the present study demonstrated that Migri‑Heal® may be useful as a potential anti‑inflammatory agent in inflammatory diseases. However, additional studies are required to confirm these findings.